Novartis successfully completes acquisition of Endocyte

Transforming patients’ lives by leading innovation in nuclear medicine

nuclear medicine R&D

Our Work

Our work is guided by our commitment to bring new innovations to patients.

AAA is developing a pipeline of nuclear medicine theragnostic pairings for oncology indications. Our theragnostic platform involves radiolabeling a targeting molecule with gallium Ga68 or fluorine F 18 to create a diagnostic radiopharmaceutical or with lutetium Lu 177 or other radionuclides used for treatment to create a therapeutic radiopharmaceutical.

Our other products include diagnostic radiopharmaceuticals for molecular imaging with Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

Look For Clinical Trials?

Find a clinical trial in your area

As part of the development process, our nuclear medicine products are evaluated in clinical trials to find new and better ways to diagnose and treat disease. These studies may be sponsored by Advanced Accelerator Applications (AAA) or by independent investigators/physicians at medical centers.

nuclear medicine clinical trials

Dec 21, 2018

Novartis successfully completes acquisition of Endocyte

Dec 3, 2018

Advanced Accelerator Applications signs exclusive option and license agreement w…

Oct 19, 2018

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonst…

Jun 22, 2018

Advanced Accelerator Applications Announces First Patients Dosed in Two Clinical…

by @adacap_news
AAA associates raising awareness and hope for #ProstateCancer patients and caregivers #HopeIsLikeAir…